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Risk of Surgical Site Infection (SSI) following Colorectal Resection
Is Higher in Patients With Disseminated Cancer: An NCCN Member
Cohort Study
Mini Kamboj, MD;1,a Teresa Childers, MPH, CIC;1,a Jessica Sugalski, MPPA;2 Donna Antonelli, BS, CPHQ;3
Juliane Bingener-Casey, MD;4 Jamie Cannon, MD;5 Karie Cluff, BSN, RN;6 Kimberly A. Davis, MD, MBA;7 E. Patchen
Dellinger, MD;8 Sean C. Dowdy, MD;9 Kim Duncan, MD;10 Julie Fedderson, MD;10 Robert Glasgow, MD;11 Bruce Hall, MD,
PhD;12 Marilyn Hirsch, RN, MS;13 Matthew Hutter, MD;14 Lisa Kimbro, MBA, CPA;2 Boris Kuvshinoff II, MD, MBA;15
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FASCRS;18 Rebekah Scott, MSN, MBA/HC, PHN, RN;18 Mindy Sovel, MPH, MA;19 Vivian Strong, MD;19 Ashley Webster,
RN, BSN, CNOR;20 Elizabeth Wick, MD;16 Julio Garcia Aguilar, MD;19 Robert Carlson, MD;2 Kent Sepkowitz, MD1,21
background. Surgical site infections (SSIs) following colorectal surgery (CRS) are among the most common healthcare-associated infec-
tions (HAIs). Reduction in colorectal SSI rates is an important goal for surgical quality improvement.
objective. To examine rates of SSI in patients with and without cancer and to identify potential predictors of SSI risk following CRS
design. American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) data ﬁles for 2011–2013 from a
sample of 12 National Comprehensive Cancer Network (NCCN) member institutions were combined. Pooled SSI rates for colorectal proce-
dures were calculated and risk was evaluated. The independent importance of potential risk factors was assessed using logistic regression.
setting. Multicenter study
participants. Of 22 invited NCCN centers, 11 participated (50%). Colorectal procedures were selected by principal procedure
current procedural technology (CPT) code. Cancer was deﬁned by International Classiﬁcation of Disease, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) codes.
main outcome. The primary outcome of interest was 30-day SSI rate.
results. A total of 652 SSIs (11.06%) were reported among 5,893 CRSs. Risk of SSI was similar for patients with and without cancer. Among
CRS patients with underlying cancer, disseminated cancer (SSI rate, 17.5%; odds ratio [OR], 1.66; 95% conﬁdence interval [CI], 1.23–2.26;
P= .001), ASA score ≥3 (OR, 1.41; 95% CI, 1.09–1.83; P= .001), chronic obstructive pulmonary disease (COPD; OR, 1.6; 95% CI, 1.06–2.53;
P= .02), and longer duration of procedure were associated with development of SSI.
conclusions. Patients with disseminated cancer are at a higher risk for developing SSI. ASA score >3, COPD, and longer duration of
surgery predict SSI risk. Disseminated cancer should be further evaluated by the Centers for Disease Control and Prevention (CDC) in
generating risk-adjusted outcomes.
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In 2016, an estimated 1.6 million new cases of cancer were
diagnosed. Prostate, lung, and colorectal are among the most
common cancers diagnosed in males. Among females, breast,
lung, and colorectal cancers are the most common.1 Colorectal
surgery offers the only curative option for localized cancer and
resectable metastatic disease. For patients with advanced can-
cer, regardless of site, colorectal surgery is undertaken as a
palliative modality to manage complications such as intestinal
obstruction or perforation.
Surgical site infection (SSIs) is a common postoperative
complication of colorectal procedures. Surgical site infections
have been associated with extended postoperative hospital
stay, readmission, morbidity, and death.2–5 Reduction in
infectious complications is a primary goal for surgical quality
programs across US hospitals.2–5 Based on the most recent
estimates from the Centers for Disease Control and Prevention
(CDC), 22% of all HAIs are SSIs, and 15% of these are asso-
ciated with colorectal procedures.6 For these reasons, lowering
SSI rates after CRS has become an observable priority.
Furthermore, SSI rates after CRS vary widely across studies,
from 3% to 30%.7,8 As a leading indication for CRS, the risk of
SSI exclusively for oncologic resection is less well studied.
A single observational study that examined more than 600
elective CRS procedures in patients with colorectal cancer
found a 30-day SSI rate of 25%.9 These ﬁndings suggest that
infectious complications fall among the higher end of the
spectrum for persons undergoing surgery for colorectal cancer.
Multicenter standardized assessment of SSI risk among
patients with cancer is not currently available.
In the early 2000s, the American College of Surgeons (ACS)
extended the National Surgical Quality Improvement Program
(NSQIP) method for risk-adjusted 30-day morbidity and
mortality outcomes after surgery from the Veterans Affairs
Healthcare system to the private sector, and SSIs are among the
outcomes examined.10,11 The ACS NSQIP is broadly used by
many healthcare facilities including several National Com-
prehensive Cancer Network (NCCN) member institutions.
The goal of this project was to examine rates of SSI following
CRS in patients with and without cancer by combining ACS
NSQIP datasets from NCCN member institutions. Among
NCCN-NSQIP participants, pooled and facility-speciﬁc rates
of SSI were examined in patients with and without cancer. For
those with underlying cancer, various baseline clinical vari-
ables and intraoperative characteristics were examined as
potential predictors of SSI risk following CRS for cancer.
methods
Data Source: American College of Surgeons National Surgical
Quality Improvement Program [ACS NSQIP]
The ACS NSQIP dataset for an institution is composed of a
systematic sample of major operations performed under
general, spinal, or epidural anesthesia. Cases are selected
through a list of current procedural terminology (CPT) codes.12
Sampling was based on consecutive selection of eligible cases
in each 8-day cycle. The data collected for eligible cases
included ~ 105 variables: 70 preoperative risk factors, 11
variables regarding the operation, and 24 postoperative out-
come variables.13 The preoperative risk factors included
demographic data and major organ-system comorbidities
described below. Preoperative laboratory values closest to the
time of the operation were also collected. Operative variables
included CPT codes, anesthesia type, American Society of
Anesthesiologists (ASA) class, wound class, and operative and
anesthesia times. Postoperative outcomes included vital status
at 30 days and 21 different postoperative complications
including SSI, return to operating room, and length of stay.
Data Acquisition
We invited 22 National Comprehensive Cancer Network
(NCCN) Member Institutions to participate in this study, and
11 centers did so: 2 standalone oncology centers and 9 large
multispecialty teaching hospitals.
Patients who had undergone incision, resection, or anasto-
mosis of the large intestine based on primary CPT codes were
identiﬁed from the ACS NSQIP databases from January 1,
2011, through December 31, 2013 (Supplementary Table 1).
Based on these query criteria, institutions were asked to submit
deidentiﬁed ACS-NSQIP data ﬁles that were subsequently
combined. A pooled oncology-speciﬁc SSI rate was derived
from this dataset based on differentiation of cancer and non-
cancer by International Classiﬁcation of Disease, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) code.
Outcomes
The primary NSQIP outcome of interest was 30-day SSI.
Patients were excluded from having an SSI if the SSI was
documented preoperatively. Crude rates of additional post-
surgical outcomes were examined among cancer and non-
cancer groups. These included 30-day mortality, readmission,
wound disruption at 30 days, and length of hospitalization.
Risk Adjustment Factors
Variables for risk adjustment included patient demographics,
preoperative risk factors, comorbidities, procedure-related risk
factors, and behavioral risk factors. Patient demographic
variables included age (18–64 or ≥65 years) and gender.
Preoperative risk variables included body mass index (BMI)
and ASA class (1–2 or ≥3). Comorbidities included diabetes
(requiring oral medication or insulin vs none), chronic
obstructive pulmonary disease, ascites, cancer (postoperative
diagnosis ICD code), disseminated cancer, chronic steroid
use, bleeding disorders, hypertension, preoperative systemic
inﬂammatory response syndrome/sepsis, and currently
requiring or on dialysis. Procedure-related risk factors inclu-
ded whether it was an emergency case, wound classiﬁcation
(contaminated or dirty), open wound (at the time of operative
procedure with or without infection), duration of procedure
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(continuous 1-minute units), >1 other procedure, surgical
approach (deﬁned by CPT), and surgical wound closure (no
layers and only deep layers of incision closed). Behavioral risk
factors included smoking status (within 1 year prior to
operation). Duration of procedure was included as a con-
tinuous variable converted into 10-minute units. All other risk
factors were converted into discrete categories.
Statistical Analysis
Postoperative diagnosis (ICD-9-CM code) was utilized to
capture patients with underlying cancer. Overall, 3,365 pro-
cedures (53.4%) had a cancer diagnostic discharge ICD-9-CM
code and were included in the cancer category. The remaining
procedures formed the noncancer cohort. Univariate analysis
was performed using χ2 tests for categorical variables, with
signiﬁcance set at P< .05. The dependent variable (SSI) was
dichotomized. Multivariate logistic regression analysis was
conducted for the entire cohort, for patients with underlying
cancer, and for the noncancer group to determine predictors
that confer risk for SSI. All statistical analyses were performed
using SAS version 9.4 software (SAS Institute, Cary, NC).
results
Baseline Characteristics and Overall SSI Rates
From January 1, 2011, to December 31, 2013, a total of 5,893
colon procedures met criteria for inclusion. Among these, 652
SSIs occurred within 30 days (overall rate, 11.06%; range,
5.93%–16.67%). The age range of the 5,893 patients was
18–101 years, with a mean of 58 years (±16.35 years) and a
median of 59 years, and 44% of these patients were men. Body
mass index was ≥30 kg/m2 in 29% of patients. A laparoscopic
approach was used in 48.6% of procedures. The mean dura-
tion of surgery was 184 minutes (±118 minutes). Mean
duration for open procedures was 202 minutes (±129.4 min-
utes), and mean duration for laparoscopic procedures was
187.6 minutes (±105.5 minutes). Major noncancer-related
comorbidities included hypertension (44%), diabetes mellitus
(12. 5%), and chronic obstructive pulmonary disease (5.1%).
Oncology-Speciﬁc SSI Rates and Localized Versus
Disseminated Cancer
Crude facility-speciﬁc SSI rates among participating hospitals
are shown in Figure 1 and Table 1. Of the 5,893 CRS patients,
3,137 (53%) had underlying cancer and 2,756 (47%) did not.
Across the multispecialty centers excluding cancer-only hos-
pitals (ie, hospitals F and H), 2,673 of 5,384 CRS (49.65%)
were cancer-related procedures. The SSI rates among the
cancer and noncancer cohorts were similar at 11 .06% and
11.07%, respectively (range, 4.81%–16.67% for those with
cancer and 0–16.9% for those without) (Table 2). The baseline
characteristics and univariate analysis are shown in Table 2.
Within the cancer cohort, 510 patients (16.3%) had dis-
seminated disease. The proportion of disseminated cancer among
all oncology cases varied across centers (range, 8.5%–27.4%).
ﬁgure 1. Facility-speciﬁc surgical site infection among 11 participating centers depicting percent of SSI in localized cancer, disseminated
cancer, and noncancer CRS patients.
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Rates of SSI in those with disseminated cancer was signiﬁcantly
higher at 17.5% versus 9.8% in those with cancer that was not
disseminated (P< .0001). Colorectal cancers constituted
~ 50% of all disseminated cancers, and the rate of SSI did not
vary by site of primary cancer (colorectal versus other, 18.2%
vs 16.7%; P= .60).
The most common type of SSI identiﬁed was superﬁcial
(n= 325, 50%), followed by organ space (n= 248, 38%) and
deep incisional (n= 79, 12.1%). Among cancer-related SSIs,
distribution of infections by localized disease was similar to
noncancer cases, with mostly superﬁcial infections (56.6% and
52%, respectively). In patients with disseminated cancer, organ-
space infections accounted for most SSIs (57%) (Table 3).
Multivariate Analysis: Study Cohort
Multivariate logistic regression models were conducted sepa-
rately for the entire cohort and the cancer and noncancer
subgroups (Table 4). Of 5,893 colon procedures, 5,765 pro-
cedures were retained as the analytic sample due to reasons
shown in Supplementary Figure 1.
In the entire cohort of patients, the following 7 variables
were statistically signiﬁcant: patients with a BMI ≥ 30 (obesity),
ASA score ≥3, diabetes, COPD, steroid or immunosuppressant
use, disseminated cancer, and duration of procedure (Sup-
plementary Table 2). The risk of SSI among patients
with underlying cancer was examined by comparing
colorectal versus other cancer types. The site of cancer was not
associated with higher risk of SSI (10.82% vs 12.07%; P= .30).
However, disseminated cancer, regardless of primary site
of origin, was signiﬁcantly associated with higher risk of
SSI (OR, 1.66; 95% CI, 1.25–2.21; P= .0005). Duration of
procedure inﬂuenced the risk for SSI. Speciﬁcally, the odds
of SSI were increased by 2% for every 10-minute increase
in procedure duration.
Multivariate Analysis: Cancer and Noncancer Subgroups
Among CRS patients with underlying cancer, ASA score ≥3
(OR, 1.41; 95% CI, 1.09–1.83; P= .001), a history of COPD
(OR, 1.6; 95% CI, 1.06–2.53; P= .02), duration of procedure
(OR, 1.002; 95% CI, 1.001–1.002; P≤ .0001), and disseminated
cancer (OR, 1.66; 95% CI, 1. 23–2.26; P= .001) predicted an
increase in SSI risk (Table 4). Diabetes, obesity, and use of
immunosuppression were not independent predictors of SSI
in the subset of patients with underlying cancer.
Among colon-surgery patients without cancer, a history of
diabetes (OR, 2.02; 95% CI, 1.41–2.92; P= .0001), duration of
procedure (OR, 1.002; 95% CI, 1.001–1.002; P≤ .0001), and
history of steroid or immunosuppressant use (OR, 1.44; 95%
CI, 1.09–1.92; P= .0111) were signiﬁcant predictors of SSI.
discussion
In our multi-institutional NCCN cohort of ~ 6,000 patients,
the mean 30-day SSI rate was 11.06%. Overall, 53% of patients
who underwent CRS procedures had underlying cancer; 16.3%
had disseminated disease. Most importantly, we found a
signiﬁcantly higher risk of SSI in patients with disseminated
cancer. The frequency of organ-space infections was also
highest among disseminated cancers when compared with the
noncancer and localized cancer categories.
Intensiﬁed efforts to reduce CRS-related SSIs are being
directed by several agencies including the Centers for Medicare
and Medicaid Services (CMS), the Surgical Care Improvement
Project (SCIP), and The Joint Commission. For benchmarking
and assessing improvement in infection-related surgical out-
comes, the CDC’s surveillance system, known as the National
Healthcare Safety Network (NHSN), and the ACS’s NSQIP are
the 2 most commonly used SSI surveillance methods.8 Each
methodology has unique advantages and limitations. While no
single method is ideal, the NSQIP has been widely adopted by
table 1. Facility-Speciﬁc Risk of SSI Among 11 Participating Centers Depicting Rate of Surgical Site Infection (SSI) in Localized Cancer,
Disseminated Cancer, and Noncancer-Related Colorectal Surgery (CRS)
Facility
No. of Procedures
(% Cancer)
(Total= 5,893)
No. of SSIs
(% Cancer)
(Total= 652)
Noncancer, SSI
Rate,
% (N= 2,756)
Localized Cancer, SSI
Rate, %
(N= 2,627)
Disseminated Cancer,
SSI Rate, %
(N= 510)
Overall SSI
Rate, %
A 705 (48.65) 102 (50.98) 13.81 13.00 24.24 14.47
B 388 (48.2) 23 (39.13) 6.97 4.68 6.25 5.93
C 819 (48.23) 124 (51.61) 14.15 15.89 17.20 15.14
D 516 (45.93) 38 (57.89) 5.73 8.42 14.29 7.36
E 1510 (54.57) 123 (52.03) 8.60 6.61 14.06 8.15
F 316 (89.97) 26 (100) 0.00 9.23 8.33 8.23
G 156 (54.59) 26 (53.85) 16.90 16.67 15.38 16.67
H 193 (93.26) 32 (93.75) 15.38 15.75 20.59 16.58
I 367 (41.42) 44 (36.36) 13.02 9.68 14.29 11.99
J 323 (54.18) 34 (55.88) 10.14 5.51 25.00 10.53
K 600 (45.83) 80 (38.75) 15.08 10.00 24.00 13.33
Overall 11.06 9.8 17.5 11.06
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table 2. Demographic Characteristics and Univariate Analysis
Surgical Site Infection
Total (%)
(n= 5,893)
Yes, No. (%)
(n= 652)
No, No. (%)
(n= 5,241) SSI % P Value
Demographics
Age
65 + y 2,345 (39.79) 2,083(39.74) 262 (40.18) 11.17 .8287
<64 y 3,548 (60.21) 3,158 (60.26) 390 (59.82) 10.99
Gender
Male 2,798 (47.48) 320 (49.08) 2,478 (47.28) 11.44 .3905
Female 3,093 (52.49) 332 (50.92) 2,761 (52.68) 10.73
Missing gender 2 (0.03) 0 (0) 2 (0.04) 0.00
Preoperative risk factors
Body mass index, kg/m2
<18.5 229 (3.89) 25 (3.83) 204 (3.89) 10.92 .0006
18.5–24.9 1,991 (33.79) 184 (28.22) 1,807 (34.38) 9.24
25–29.9 1,865 (31.65) 196 (30.06) 1,669 (31.85) 10.51
≥30 1,715 (29.10) 234 (35.89) 1,481 (28.26) 13.64
Missing BMI 93 (1.58) 13 (1.99) 80 (1.53) 13.98
ASA class
ASA ≥3 2,793 (47.40) 413 (63.34) 2,685 (51.23) 14.79 <.0001
ASA<3 3,098 (52.57) 238 (36.5) 2,555 (48.75) 7.68
Missing ASA 2 (0.03) 1 (0.15) 1 (0.02) 50.00
Procedure-related risk factors
Emergency case
Yes 610 (10.35) 78 (11.96) 532 (10.15) 12.79 .1519
No 5,283 (89.65) 574 (88.04) 4,709 (89.85) 10.87
Wound classiﬁcation
Contaminated or dirty/infection 1,400 (23.76) 184 (28.22) 1,216 (23.20) 13.14 .0045
Clean or clean contaminated 4493 (76.24) 468 (71.78) 4,025 (76.8) 10.42
Open wound
Yes 175 (2.97) 17 (2.61) 158 (3.01) 9.71 .5634
No 5,718 (97.03) 635 (97.39) 5,083 (96.99) 11.11
Mean duration, min 195.07
(SD, 118.62)
227.1
(SD, 145.9)
191.1
(SD, 114.2)
<.0001
>1 Procedure
>1 Other procedures 1,384 (23.49) 176 (26.99) 1,208 (23.05) 12.72 .025
≤1 Other procedure 4,509 (76.41) 476 (73.01) 4,033 (76.95) 10.56
Surgical approach
Open 3,028 (51.38) 377 (57.82) 2,651 (50.58) 12.45 .0005
Laparoscopic 2,865 (48.62) 275 (42.18) 2,590 (49.42) 9.60
Wound closure
Only deep or no layers closed 152 (2.58) 15 (2.3) 137 (2.61) .7964
All layers closed 3,887 (65.96) 409 (62.73) 3,478 (66.36)
Missing wound closure 1,854 (31.46) 228 (34.97) 1,626 (31.02)
Comorbidities
Diabetes
Yes 737 (12.51) 123 (18.87) 614 (11.72) 16.69 <.0001
No 5,156 (87.49) 529 (81.13) 4,627 (88.28) 10.26
COPD
Yes 298 (5.06) 55 (8.44) 243 (4.64) 18.46 <.0001
No 5,595 (94.94) 597 (91.56) 4,498 (95.36) 10.67
Ascites 30 days prior to surgery
Yes 79 (1.34) 15 (2.3) 64 (1.22) 18.99 .0238
No 5,814 (98.66) 637 (97.7) 5,177 (98.78) 10.96
Cancer ICD-9 or disseminated
Yes 3,137 (53.23) 347 (53.22) 2,790 (53.23) 11.06 .9949
No 2,756 (46.77) 305 (46.78) 2,451 (46.77) 11.07
Disseminated cancer
Yes 510 (8.65) 89 (13.65) 421 (8.03) 17.45 <.0001
No 5,383 (91.35) 563 (86.85) 4,820 (91.97) 10.46
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table 2. Continued
Surgical Site Infection
Total (%)
(n= 5,893)
Yes, No. (%)
(n= 652)
No, No. (%)
(n= 5,241) SSI % P Value
Chronic steroid use
Yes 859 (14.58) 112 (17.18) 747 (14.25) 13.04 .0459
No 5,034 (85.42) 540 (82.82) 4,494 (85.75) 10.73
Bleeding disorders
Yes 283 (4.8) 38 (5.83) 245 (4.67) 13.43 .1939
No 5,610 (95.2) 614 (94.17) 4,996 (95.33) 10.94
Hypertension
Yes 2,585 (43.87) 327 (51.15) 2,258 (43.08) 12.65 .0006
No 3,308 (56.13) 325 (49.85) 2,983 (56.92) 9.82
Preoperative SIRS/sepsis
Yes 613 (10.4) 77 (11.81) 536 (10.23) 12.56 .2119
No 5,280 (89.6) 575 (88.19) 4,705 (89.77) 10.89
Dialysis
Yes 59 (1.0) 8 (1.23) 51 (0.97) 13.56 .5391
No 5,834 (99.0) 644 (98.77) 5,190 (99.03) 11.04
Behavioral risk factors
Smoking status
Yes 967 (16.41) 127 (19.48) 840 (16.03) 13.13 .0248
No 4,926 (83.59) 525 (80.52) 4,401 (83.97) 12.22
NOTE. SSI, Surgical Site Infection; BMI, body mass index; ASA, American Society of Anesthesiologists physical status; COPD,
chronic obstructive pulmonary disease; ICD-9, International Classiﬁcation of Diseases, Ninth Edition; SIRS, systemic
inﬂammatory response syndrome.
table 3. Depth of Surgical Site Infection (SSI) Among 3 Groups
Overall No Cancer
Localized
Cancer
Disseminated
Cancer
SSI Depth Frequency % Frequency % Frequency % Frequency %
Superﬁcial 325 49.8 158 51.8 146 56.6 21 23.6
Deep 79 12.1 35 11.48 26 10.1 18 20.2
Organ Space 248 38 112 36.72 86 33.3 50 56.1
Total 652 305 258 89
table 4. Multivariate Analysis: Surgical Site Infections (SSIs) Among All Colorectal Surgery (CRS) Patients, CRS Patients With Cancer,
and CRS Patients Without Cancer
Total (n= 5,765) Underlying Cancer (n= 3,094) Noncancer (n= 2,671)
635 (11.01) 341 (11.02) 294 (11.01)
No. of SSIs (%) OR 95% CI P Value Overall No Cancer P Value OR CI 95% P Value
BMI, ≥30 kg/m2 vs (18.5– 24.9) 1.349 1.08–1.68 .0076 1.419 1.01–1.92 .0236 1.293 0.93–1.79 .1216
ASA ≥3 1.326 1.10–1.61 .0037 1.412 1.09–1.83 .0097 1.206 0.91–1.60 .1948
History of diabetes 1.453 1.15–1.85 .0021 1.139 0.83–1.56 .4248 2.028 1.41–2.92 .0001
COPD 1.589 1.14–2.22 .0063 1.639 1.06–2.53 .0253 1.600 0.95–2.70 .0803
Disseminated cancer 1.658 1.25–2.21 .0005 1.669 1.23–2.26 .001 … n/a …
Duration of procedure 1.002 1.001–1.002 <.0001 1.002 1.001–1.002 .0001 1.002 1.001–1.003 < .0001
Chronic steroid use 1.317 1.04–1.67 .0224 1.060 0.66–1.71 .8075 1.443 1.09–1.92 .0111
NOTE. BMI, body mass index; ASA, American Society of Anesthesiologists physical status; COPD, chronic obstructive pulmonary disease; n/a, not
available.
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surgical quality programs in the last decade to assess risk-
adjusted performance and to identify potential predictors
of SSIs.
The CDC NHSN is the nation’s most widely used
healthcare-associated infection tracking system. Beginning in
2012, hospitals participating in the CMS Inpatient Prospective
Payment System (IPPS) are required to report SSI data
through the NHSN, which are accessible at the Hospital
Compare website.14 Generally, the NHSN has used 3 patient-
level factors to determine the risk index for all SSIs: ASA score,
wound classiﬁcation, and procedure duration. Due to the poor
performance of the NHSN risk index in predicting SSIs based
on these limited variables, procedure-speciﬁc risk prediction
models were subsequently created.15 Patient-speciﬁc variables,
especially those related to cancer surgeries, a leading indication
for colorectal resection, are not currently included.
Disseminated cancer has previously been associated with
higher risk of SSI. In a report that included 740 patients under-
going CRS for neoplastic disease, Bot et al16 found the risk of all
postoperative infection complications to be higher among
patients with advanced tumors (stage ≥ IIB) compared to those
with local disease. These differences were largely due to higher
rates of anastomotic leakage in the group with advanced tumors
(14.1% vs 5.6%; P= .001). The frequency of superﬁcial SSIs was
similar in both groups.16 Segal et al17 found a similar association
of disseminated cancer with organ space SSIs (adjusted odds ratio
[AOR], 1.21; 95% CI, 1.02–1.44).17
Data on the impact of various prevention efforts, speciﬁcally
for OS SSIs are limited.18 Strictly in the context of
disseminated cancer, it is plausible that the risk of SSI may be
modiﬁable with the use of neoadjuvant strategies. However,
SSI has never been formally evaluated as an outcome with such
approaches. For advanced metastatic disease, this risk may not
be changeable or direct meaningful modiﬁcation in prevention
efforts. For these reasons, a closer evaluation of disseminated
cancer as a risk index in the NHSN model is essential.
This study contributes several other important ﬁndings.
Apart from rates of SSI among disseminated cancer, the overall
SSI rates in this study are comparable to those reported by
large medical centers in the United States within a similar
period.8,18 In a 2012 study by Ju et al,8 the pooled NSQIP
CRS-SSI rate from 16 teaching hospitals in the United States
was 13.5%. Although the study included 11 American Cancer
Society (ACS)–accredited centers, cancer-speciﬁc risk was not
speciﬁcally determined.8 In another large multi-institutional
study from 7 multispecialty centers (~7,500 CRS procedures),
the pooled SSI rate was 10.7%.18 Other variables that predicted
SSI risk in our cohort were BMI > 30 kg/m2 (obesity),
diabetes, ASA score >3, COPD, immunosuppressant and/or
steroid use, and longer duration of surgery. Many of these risk
factors have previously been identiﬁed as predictors of SSI risk
among patients undergoing CRS. This study further corrobo-
rates the ﬁndings from previous reports distinctively in cancer-
related CRS (Table 4). Perioperative hyperglycemia in patients
with diabetes has been found to increase the risk of developing
postoperative nosocomial infection.3,9–21 In this study,
diabetes increased the odds of developing SSI by 2-fold in the
noncancer group; however, no signiﬁcant association with
SSI risk was observed among patients with cancer. The small
sample size, lack of an assessment of glycemic control, espe-
cially in the perioperative period, and uncertain duration of
diabetes at the time of surgery are factors that may explain this
nonsigniﬁcant ﬁnding.19 Larger studies are needed to further
examine this relationship speciﬁcally among oncology
procedures.
The strengths of this study include the fact that it leverages
the NCCN infrastructure to examine cancer-related risk of SSI
across several institutions. It validates disseminated cancer as
a signiﬁcant predictor of SSI risk among cancer patients
undergoing CRS. This study has several limitations and
potential biases, such as the effective “survey response rate” of
55% of invited institutions. Although hospital characteristics
were not speciﬁcally collected, NSQIP hospitals are somewhat
more likely to be large academic centers and, therefore, our
ﬁndings are not generalizable to all US hospitals. Oncology-
related variables including chemotherapy and radiation were
not available. The breakdown of cancer versus noncancer was
based on ICD-9 diagnoses and was subject to coding errors
resulting in misclassiﬁcation of cases. Not all risk factors by
level of infection were examined. We were unable to stratify
risk of SSI by stage of cancer because these data are not
currently captured in NSQIP. Finally, data on best practices
implemented at each center and SSI prevention initiatives were
not collected, which could account for differences in observed
interfacility rates and inﬂuence the SSI risk model.
In conclusion, cancer is one of the most common indica-
tions for CRS regardless of facility type (cancer hospital or
other). The ﬁndings from the current study derived from the
NSQIP dataset of NCCN hospitals conﬁrm the association of
disseminated cancer with risk of SSI and propose its evaluation
in NHSN’s multivariate model. This is achievable with the
inclusion of the disseminated cancer variable (ICD-10) with
procedural entry of cancer-related surgeries.
Although standardization across 2 of the most widely used
surveillance methodologies (NSQIP and NHSN) is unlikely to
occur due to marked variation in data collection and analysis
techniques, the information gained from one surveillance system
should be validated in the other to reﬁne existing
risk-adjustment methods. Constant reevaluation with new
informationwill ultimately provide external benchmarks that can
be reliably applied to measure performance of prevention efforts.
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